TNFRSF8 and Hodgkins lymphoma: Importantly, patients with relapsed or refractory Hodgkin lymphoma (HL) showed a high rate of durable responses with an excellent safety profile following treatment with CD30-specific CAR-Ts (CD30.CAR-T).